头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌血症 - Suppr

Suppr

超能文献

Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia.

作者信息

Wu Gary, Abraham Teena, Lee Spencer

机构信息

Department of Pharmacy, New York Methodist Hospital, Brooklyn.

出版信息

Clin Infect Dis. 2016 Oct 15;63(8):1147-8. doi: 10.1093/cid/ciw491. Epub 2016 Jul 17.

DOI:10.1093/cid/ciw491

PMID:27432841

Abstract

摘要

相似文献

Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia.

Clin Infect Dis. 2016 Oct 15;63(8):1147-8. doi: 10.1093/cid/ciw491. Epub 2016 Jul 17.

Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.

Int J Infect Dis. 2021 Aug;109:1-7. doi: 10.1016/j.ijid.2021.05.079. Epub 2021 Jun 4.

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00449-17. Print 2017 Jul.

Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat".

Clin Infect Dis. 2016 Dec 15;63(12):1619-1621. doi: 10.1093/cid/ciw639. Epub 2016 Sep 13.

Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.

Int J Antimicrob Agents. 2018 Apr;51(4):629-635. doi: 10.1016/j.ijantimicag.2018.01.016. Epub 2018 Feb 2.

Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.

Int J Antimicrob Agents. 2017 Jun;49(6):770-773. doi: 10.1016/j.ijantimicag.2017.01.018. Epub 2017 Apr 4.

Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.

Int J Antimicrob Agents. 2018 Mar;51(3):511-515. doi: 10.1016/j.ijantimicag.2018.01.011. Epub 2018 Jan 31.

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.

Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00642-17. Print 2017 Sep.

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.

Int J Infect Dis. 2017 Jun;59:118-123. doi: 10.1016/j.ijid.2017.03.021. Epub 2017 Apr 6.

引用本文的文献

Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.

Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.

Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.

J Clin Microbiol. 2022 Mar 16;60(3):e0224521. doi: 10.1128/jcm.02245-21.

Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics.

Antibiotics (Basel). 2021 Nov 30;10(12):1473. doi: 10.3390/antibiotics10121473.

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review.

Infect Dis Ther. 2021 Dec;10(4):1989-2034. doi: 10.1007/s40121-021-00507-6. Epub 2021 Aug 11.

Emergence of the New KPC-49 Variant Conferring an ESBL Phenotype with Resistance to Ceftazidime-Avibactam in the ST131-H30R1 High-Risk Clone.

Pathogens. 2021 Jan 14;10(1):67. doi: 10.3390/pathogens10010067.

New Delhi Metallo-beta-lactamase-producing Enterobacter Cloacae - A Rare Multidrug Resistance Strain in a Caucasian Woman.

Cureus. 2020 Mar 4;12(3):e7177. doi: 10.7759/cureus.7177.

capsule polysaccharide as a target for therapeutics and vaccines.

Comput Struct Biotechnol J. 2019 Oct 25;17:1360-1366. doi: 10.1016/j.csbj.2019.09.011. eCollection 2019.

Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Dtsch Arztebl Int. 2018 May 21;115(20-21):345-352. doi: 10.3238/arztebl.2018.0345.

The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Curr Infect Dis Rep. 2018 May 5;20(6):13. doi: 10.1007/s11908-018-0617-x.

Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验